Literature DB >> 1331248

Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients.

G Gerna1, D Zipeto, E Percivalle, M Parea, M G Revello, R Maccario, G Peri, G Milanesi.   

Abstract

Fourteen immunocompromised patients were examined for viremia, pp65 and p72 antigenemia, and presence of viral DNA in leukocyte fractions of polymorphonuclear leukocytes (PMNL), monocytes/macrophages (M/M), and B and T lymphocytes after purification by fluorescence-activated cell sorting. Nearly all PMNL and M/M fractions were positive for DNA and pp65 antigenemia, while p72 antigenemia was detected in 73% and 62%, respectively. The virus isolation rate was 45% from PMNL and 17% from M/M. T lymphocytes were positive for DNA in 50% of cases and for pp65 and p72 antigenemia in only 11%, while B lymphocytes were DNA-positive in 43% of samples and consistently negative for antigenemia; neither T nor B lymphocytes had virus isolated. Immediate-early (IE)1 RNA was present in 23 (85.2%) of 27 dextran-enriched DNA-positive p72-positive PMNL samples and, in sequential PMNL samples from two heart-transplanted patients, was detected during peak infection in association with p72. Thus, PMNL and M/M are the subpopulations primarily involved in HCMV infection; PMNL may undergo IE replicative events and are not merely passive carriers of phagocytized viral material.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1331248     DOI: 10.1093/infdis/166.6.1236

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  51 in total

Review 1.  Human cytomegalovirus infection and atherothrombosis.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

2.  Human cytomegalovirus replicates abortively in polymorphonuclear leukocytes after transfer from infected endothelial cells via transient microfusion events.

Authors:  G Gerna; E Percivalle; F Baldanti; S Sozzani; P Lanzarini; E Genini; D Lilleri; M G Revello
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Prolonged activation of NF-kappaB by human cytomegalovirus promotes efficient viral replication and late gene expression.

Authors:  Ian B DeMeritt; Jagat P Podduturi; A Michael Tilley; Maciej T Nogalski; Andrew D Yurochko
Journal:  Virology       Date:  2005-11-21       Impact factor: 3.616

Review 4.  Uses of flow cytometry in virology.

Authors:  J J McSharry
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

5.  Rapid cytomegalovirus pp65 antigenemia assay by direct erythrocyte lysis and immunofluorescence staining.

Authors:  S K Ho; C Y Lo; I K Cheng; T M Chan
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

6.  Comparison of two leukocyte extraction methods for cytomegalovirus antigenemia assay.

Authors:  A García; J Niubò; M A Benítez; M Viqueira; J L Pérez
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

7.  Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors.

Authors:  P Grossi; S Kusne; C Rinaldo; K St George; M Magnone; J Rakela; J Fung; T E Starzl
Journal:  Transplantation       Date:  1996-06-15       Impact factor: 4.939

Review 8.  Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation.

Authors:  Raymund R Razonable; Randall T Hayden
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

9.  Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence.

Authors:  M Shane Smith; Gretchen L Bentz; J Steven Alexander; Andrew D Yurochko
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Activation of the NF-kappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter.

Authors:  Ian B DeMeritt; Liesl E Milford; Andrew D Yurochko
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.